PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC 50 of 0.7 nM.
性状
Solid
IC50 & Target[1][2]
IC50: 0.7 nM (EGFR tyrosine kinase)
体外研究(In Vitro)
Pretreatment with PKI-166 (0-0.5 μM; 1 hour) inhibits EGFR autophosphorylation in human pancreatic cancer cells.PKI-166 (0.03μ M; 6 days) enhanced the cytotoxicity mediated by gemcitabine. has not independently confirmed the accuracy of these methods. They are for reference only.Western Blot Analysis-tbl">
体内研究(In Vivo)
PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Male athymic nude mice with L3
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 Jun 1;60(11):2926-35.